The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | A study investigating the efficacy of dual-targeting bispecifics/CAR-Ts in a large cohort
Muhammad Bilal Abid, MD, UT Houston McGovern School of Medicine, Houston, TX, discusses a study investigating the efficacy of dual-targeting bispecific/CAR-T regimens in a large cohort of patients with varying malignancies. The study found an overall response rate (ORR) of nearly 70%, and grade 3 cytokine release syndrome (CRS) was comparable to pivotal single-antigen-targeting CAR-T trials. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
